Pancragen Forte: four weeks in 12 older adults with impaired glucose tolerance
Observational study · 2013
- What was studied
- 12 older adults with impaired glucose tolerance received treatment. The screening sample included 150 people across three age groups, of whom 69 were 60 or older.
- Main finding
- After four weeks of Pancragen Forte at 500 µg twice daily, the authors reported lower glucose during a tolerance test in half of the 12 treated adults. The abstract leaves the size of the change and the response threshold unspecified.
Reported findings and study design
The 12-person intervention used 500 µg of Pancragen Forte twice daily, morning and evening, for four weeks. The investigators used a 75 g oral glucose tolerance test with blood sampling before and at 30, 60 and 120 minutes. They also assessed HbA1c, proinsulin and indices of insulin resistance and sensitivity.
Population or model 12 older adults with impaired glucose tolerance received treatment. The screening sample included 150 people across three age groups, of whom 69 were 60 or older.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported glucose response | Half of the 12 treated adults had a reported decrease in plasma glucose on testing. | After four weeks |
| Lipids, endothelial function and platelet aggregation | The authors reported favorable changes qualitatively. The abstract gives no arm-level numerical estimates. |
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- The available abstracts describe a treated subgroup and leave the control comparison and masking unspecified. The 150 screened people do not represent treatment enrollment.
- The formulation was Pancragen Forte. The abstracts leave the administration route and product composition unspecified. This impaired-glucose-tolerance report is distinct in design from the authors’ earlier study in established type 2 diabetes.
Source details
Original journal report
Original Russian and English abstracts, including dose schedule and screening counts.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
O. V. Korkushko, V. P. Chizhova, V. B. Shatilo, V. Kh. Khavinson. Pancragen Forte: four weeks in 12 older adults with impaired glucose tolerance Advances in Gerontology. 2013;26(2):297–308.